Alan G. Walton

Founder at Exelixis, Inc.

Alan G. Walton

Alan G. Walton

Founder at Exelixis, Inc.

Career Highlights

Oxford Bioscience Corporation
Oxford Bioscience III Corporation
University Genetics Co.

RelSci Relationships


Number of Boards






Number of Awards


Contact Data
Trying to get in touch with Alan G. Walton? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
RelSci Relationships are individuals Alan G. Walton likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Avalon Pharmaceuticals, Inc.

Relationship likelihood: Strong

Managing General Partner at Oxford Bioscience Partners

Relationship likelihood: Strong

Founder at Noble Bioventures LLC

Relationship likelihood: Strong

Co-Founder at Exelixis, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Exelixis, Inc.

Relationship likelihood: Strong

Chief Clinical Advisor at Accelerated Pharma, Inc.

Relationship likelihood: Strong

Investor at Check Point Software Technologies Ltd.

Relationship likelihood: Strong

Vice President of Finance at Flagship Pioneering

Relationship likelihood: Strong

President & Chief Executive Officer at Vir Biotechnology, Inc.

Relationship likelihood: Strong

Former Executive Chairman at Aciex Therapeutics, Inc.

Relationship likelihood: Strong

In The News
Paths to Alan G. Walton
Potential Connections via
Relationship Science
Alan G. Walton
Founder at Exelixis, Inc.
PhD in Chemistry

The University of Nottingham shares many of the characteristics of the world's great universities. However, they are distinct not only in their key strengths but in how their many strengths combine: they are financially secure, campus based and comprehensive; they are research-led and recruit top students and staff from around the world; they are committed to internationalising all their core activities so their students can have a valuable and enjoyable experience that prepares them well for the rest of their intellectual, professional and personal lives.

Career History
1994 - Current

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

General Partner
1987 - Current
Senior Partner & Chairman
Boards & Committees
2003 - Current

Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations.

Founding Chairman

NetGenics, Inc. develops software solutions for life science research. The firm provides bioinformatics solutions including the use of information technology by life science research companies to convert massive amounts of data into useful information that their scientists can then use in the development of new drugs, gene therapies, and agricultural products. The company was founded in 1996 and is headquartered in Cleveland, OH.

Political Donations

Former President of United States


Co-Founder at Empower Schools

Details Hidden

Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD.

Awards & Honors
The University of Nottingham
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alan G. Walton. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alan G. Walton's profile does not indicate a business or promotional relationship of any kind between RelSci and Alan G. Walton.